Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients

References

• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377.
   PubMed Web of Science ®Google Scholar
• Setty AR, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep. 2007;9(6):449.
   PubMedGoogle Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl_2):ii14–7.
   PubMedGoogle Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
   Web of Science ®Google Scholar
• Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol. 2020;214:108397.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–255.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasisfoundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712.
   PubMed Web of Science ®Google Scholar
• Østensen M. Sexual and reproductive health in rheumatic disease. Nat Rev Rheumatol. 2017;13(8):485–493.
   PubMed Web of Science ®Google Scholar
• Phillips R, Pell B, Grant A, et al. Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. BMC Rheumatol. 2018;2(21). 10.1186/s41927-018-0029-4.
   PubMedGoogle Scholar
• De Simone C, Caldarola G, Moretta G, et al. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol. 2019;154(3):305–314.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
   PubMed Web of Science ®Google Scholar
• Shi Y, Chen Z, Zhao Z, et al. IL-21 induces an imbalance of Th17/treg cells in moderate-to-severe plaque psoriasis patients. Front Immunol. 2019;10:1865.
   PubMed Web of Science ®Google Scholar
• Meer Y, Rudi T, Fischer-Betz R, et al. Pregnancy in women with psoriatic arthritis: a systematic literature review of disease activity and adverse pregnancy outcomes. Seminars in Arthritis and Rheumatism (Accepted 2021 Apr 13rd).
   Google Scholar
• Mouyis MA, Thornton CC, Williams D, et al. Pregnancy outcomes in patients with psoriatic arthritis. J Rheumatol. 2017;44(1):128–129.
   PubMed Web of Science ®Google Scholar
• Murray K, Moore L, McAuliffe F, et al. Reproductive health outcomes in women with psoriatic arthritis. Ann Rheum Dis. 2019;78(6):850–852.
   PubMed Web of Science ®Google Scholar
• Ursin K, Lydersen S, Skomsvoll JF, et al. Psoriatic arthritis disease activity during and after pregnancy: a prospective multicenter study. Arthritis Care Res. 2019;71(8):1092–1100.
   Web of Science ®Google Scholar
• Berman M, Zisman D, Wollman J, et al. The effect of pregnancy on disease activity in patients with psoriatic arthritis. J Rheumatol. 2018;45(12):1651–1655.
   PubMed Web of Science ®Google Scholar
• Polachek A, Polachek Shlomi I, Spitzer K, et al. Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. Clin Rheumatol. 2019;38(3):895–902.
   PubMed Web of Science ®Google Scholar
• Remaeus K, Stephansson O, Johansson K, et al. Maternal ad infant pregnancy outcomes in women with psoriatic arthritis. BJOG. 2019;126(10):1213–1222.
   PubMed Web of Science ®Google Scholar
• Bröms G, Haerskjold A, Granath F, et al. Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol. 2018;98(8):728–734.
   PubMed Web of Science ®Google Scholar
• Smith CJF, Bandoli G, Kavanaugh A, et al. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. Arthritis Care Res (Hoboken). 2019;71(8):1019–1027.
   Google Scholar
• Polachek A, Li S, Polachek IS, et al. Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. Semin Arthritis Rheum. 2017;46(740–45):740–745.
   PubMedGoogle Scholar
• Ostensen M, Ostensen H. Ankylosing spondylitis–the female aspect. J Rheumatol. 1998;25(1):120–124.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Milardi D, Grande G, et al. Untreated psoriasis impairs male fertility: a case-control study. Dermatology. 2017;233(2–3):170–174.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–1110.
   PubMed Web of Science ®Google Scholar
• Finelli R, Leisegang K, Finocchi F, et al. The impact of autoimmune systemic inflammation and associated medications on male reproductive health in patients with chronic rheumatological, dermatological, and gastroenterological diseases: a systematic review. Am J Reprod Immunol. 2021;85(5):e13389.
   PubMed Web of Science ®Google Scholar
• Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol. 2017;13(1):51–58.
   PubMed Web of Science ®Google Scholar
• Ley D, Jones J, Parrish J, et al. Methotrexate reduces DNA integrity in sperm from men with inflammatory bowel disease. Gastroenterology. 2018;154(8):2064–2067.
   PubMed Web of Science ®Google Scholar
• Heppt F, Colsman A, Maronna A, et al. Influence of TNF-alpha inhibitors and fumaric acid esters on male fertility in psoriasis patients. J Eur Acad Dermatol Venereol. 2017;31(11):1860–1866.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis. 2010;69(10):1842–1844.
   PubMed Web of Science ®Google Scholar
• Vasta V, Shimizu-Albergine M, Beavo JA. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci U S A. 2006;103(52):19925–19930.
   PubMed Web of Science ®Google Scholar
• Boots CE, Jungheim ES. Inflammation and human ovarian follicular dynamics. Semin Reprod Med. 2015;33(4):270–275.
   PubMed Web of Science ®Google Scholar
• Flint J, Panchal S, Hurrell A, et al. BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55(9):1693–1697.
   PubMed Web of Science ®Google Scholar
• Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.
   PubMed Web of Science ®Google Scholar
• Sammaritano LR, Bermas BL, Chakravarty EE, et al., American College of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529–556.
   PubMed Web of Science ®Google Scholar
• Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum. 2019;48(5):911–920.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–292.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019;71(1):2–29.
   Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68(11):1793–1794.
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(2):414–417.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety Database. Arthritis Rheumatol. 2018;70(9):1399–1407.
   PubMed Web of Science ®Google Scholar
• Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017;76(38–52):38–52.
   PubMedGoogle Scholar
• Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–605.
   PubMed Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20(3):495–501.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11(174). DOI:10.1186/1741-7015-11-174
   PubMedGoogle Scholar
• Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):451–462.
   PubMed Web of Science ®Google Scholar
• Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNF alpha use throughout pregnancy: possible complications for the mother but not for the fetus. a retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol. 2018;113(11):1669–1677.
   PubMed Web of Science ®Google Scholar
• Duricova D, Dvorakova E, Hradsky O, et al. Safety of Anti-TNF-Alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis. 2019;25(4):789–796.
   PubMed Web of Science ®Google Scholar
• Ramonda R, Foresta C, Ortolan A, et al. Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril. 2014;101(2):359–365.
   PubMed Web of Science ®Google Scholar
• Larsen MD, Friedman S, Magnussen B, et al. Birth outcomes in children fathered by men treated with anti-TNF-α agents before conception. Am J Gastroenterol. 2016;111(11):1608–1613.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, Van Der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550–1558.
   PubMed Web of Science ®Google Scholar
• Kumar M, Ray L, Vemuri S, et al. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 2015;45(3):351–356.
   PubMed Web of Science ®Google Scholar
• Saito J, Yakuwa N, Takai C, et al. Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment: a case study. Rheumatology (Oxford). 2019;58(9):1692–1694.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–1626.
   PubMed Web of Science ®Google Scholar
• Van Mourik MSM, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J Leukoc Biol. 2009;85(1):4–19.
   PubMed Web of Science ®Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–363.
   PubMed Web of Science ®Google Scholar
• Naureckas S, Slater J, Gearhart N, et al. Pregnancy outcomes in women with psoriasis and psoriatic arthritis exposed to ustekinumab. J Am Acad Dermatol. 2016;74(Suppl 1):AB264.
   Google Scholar
• Ellen S, Douglas J, Conor M, et al. Pregnancy outcomes in women exposed to ustekinumab in the Crohn’s disease clinical development program. Am J Gastroenterol. 2018;113(S4):S4.
   Google Scholar
• Mahadevan U, Naureckas S, Sharma B, et al. Pregnancy outcomes in women exposed to ustekinumab. Gastroenterology. 2018;6(Suppl 1):588–589.
   Google Scholar
• Rowan C, Culen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with crohn’s disease treated until 33 weeks of gestation. J Crohn’s Colitis. 2018;12(83):376–378.
   Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical pathway: a report from the American gastroenterologic association IBD parenthood project working group. Gastroenterology. 2019;156(5):1508–1524.
   PubMed Web of Science ®Google Scholar
• Klenske E, Osaba L, Nagore D, et al. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with crohn’s disease. J Crohns Colitis. 2019;13(2):267–269.
   PubMed Web of Science ®Google Scholar
• Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper. J Cutan Med Surg. 2020;24(1_suppl):3S–14S.
   PubMed Web of Science ®Google Scholar
• Haycraft K, DiRuggiero D, Rozzo SJ, et al. Outcomes of pregnancies from the tildrakizumab phase I-III clinical development programme. Br J Dermatol. 2020;183(1):184–186.
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
   PubMed Web of Science ®Google Scholar
• Clarke DO, Hilbish KG, Waters DG, et al. Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys. Reprod Toxicol. 2015;58:160–173.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–2500.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39(8):755–762.
   PubMed Web of Science ®Google Scholar
• FDA and CDER. Xeljanz (tofacitinib) [package insert]. New York, NY: Pfizer Inc, 1–33 (2012).
   Google Scholar
• Costanzo G, Firinu D, Losa F, et al. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X19899296.
   Web of Science ®Google Scholar
• Vinet E, Chakravarty EF, Clowse MEB. Power in numbers. Rheumatology (Oxford). 2018;57(suppl_5):v40–v47.
   PubMedGoogle Scholar
• https://mothertobaby.org. Access date 2021 February 01.
   Google Scholar
• Meissner Y, Fischer-Betz R, Andreoli L, et al. EULAR recommendations for a core data set for pregnancy registries in rheumatology. Ann Rheum Dis. 2021;80(1):49–56.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Feb 12]. Available from:https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf
   Google Scholar